Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.

[1]  V. Reddy,et al.  Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device , 2021, Circulation.

[2]  M. Price,et al.  The NCDR Left Atrial Appendage Occlusion Registry. , 2020, Journal of the American College of Cardiology.

[3]  D. Delurgio,et al.  Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries. , 2019, Journal of the American College of Cardiology.

[4]  V. Reddy,et al.  Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes , 2018, Circulation.

[5]  Saibal Kar,et al.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.

[6]  S. Kische,et al.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.

[7]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[8]  M. Price,et al.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.

[9]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[10]  K. Anstrom,et al.  Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. , 2013, JAMA.

[11]  J. Messenger,et al.  The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.

[12]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[13]  D. Packer,et al.  The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. , 2006, American heart journal.